Detalhe da pesquisa
1.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
2.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
3.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
4.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
5.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
6.
Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.
HIV Med
; 23(4): 390-396, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243750
7.
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Clin Infect Dis
; 70(10): 2073-2081, 2020 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31340042
8.
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients.
J Infect Dis
; 211(2): 178-86, 2015 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25081936
9.
Efficacy and safety of darunavir/ritonavir plus etravirine dual regimen in antiretroviral therapy-experienced patients: a multicenter clinical experience.
HIV Clin Trials
; 15(4): 140-50, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25143023
10.
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
J Antimicrob Chemother
; 68(1): 200-5, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22915463
11.
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.
JHEP Rep
; 5(11): 100885, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37791379
12.
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.
BMC Infect Dis
; 11: 23, 2011 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21266068
13.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335323
14.
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
HIV Med
; 11(2): 104-13, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19732176
15.
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Sci Transl Med
; 12(548)2020 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32554708
16.
A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Front Immunol
; 9: 3175, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30713538
17.
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
AIDS
; 21(5): 599-606, 2007 Mar 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-17314522
18.
Pathophysiology of ischaemic heart disease.
Curr Opin HIV AIDS
; 12(6): 548-553, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28984703
19.
Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort.
J Acquir Immune Defic Syndr
; 74(3): 347-352, 2017 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27828874
20.
Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
Antivir Ther
; 11(5): 609-18, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16964829